Baltic Post-marketing Study of Pegilated Interferon α-2a 40 KD Efficacy and Safety in Patients with HBeAg–Positive and HBeAg– Negative Chronic Hepatitis B

Ludmila Viksna^1,2*, Agita Jeruma^1,2, Gunta Sture^1,2, Baiba Rozentale^1,2, Andrejs Ivanovs¹, Jazeps Keiss² and Valentina Sondore²

¹Department of Infectology and Dermatology, Riga Stradins University, Linezera Street 3, LV-1006, Riga, Latvia

²Latvian Centre of Infectious Diseases, Riga East University Hospital, Linezera Street 3, LV-1006, Riga, Latvia

^*Corresponding Author: Ludmila Viksna, Department of Infectology and Dermatology, Riga Stradins University, Linezera Street 3, LV-1006, Riga, Latvia, Tel: +371 67014717 Email: